prikaz prve stranice dokumenta Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling
Access restricted to students and staff of home institution
Scientific paper - Original scientific paper
Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling
Biochemical and Biophysical Research Communications, 503 (2018), 2; 843-848. https://doi.org/10.1016/j.bbrc.2018.06.085
Klobučar, Marko; Grbčić, Petra; Pavelić, Sandra Kraljević; Jonjić, Nives; Visentin, Sarah; Sedić, Mirela

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Klobučar, M., Grbčić, P., Pavelić, S. K., Jonjić, N., Visentin, S. & Sedić, M. (2018). Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling. Biochemical and Biophysical Research Communications, 503. (2), 843-848. doi: 10.1016/j.bbrc.2018.06.085

Klobučar, Marko, et al. "Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling." Biochemical and Biophysical Research Communications, vol. 503, no. 2, 2018, pp. 843-848. https://doi.org/10.1016/j.bbrc.2018.06.085

Klobučar, Marko, Petra Grbčić, Sandra Kraljević Pavelić, Nives Jonjić, Sarah Visentin and Mirela Sedić. "Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling." Biochemical and Biophysical Research Communications 503, no. 2 (2018): 843-848. https://doi.org/10.1016/j.bbrc.2018.06.085

Klobučar, M., et al. (2018) 'Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling', Biochemical and Biophysical Research Communications, 503(2), pp. 843-848. doi: 10.1016/j.bbrc.2018.06.085

Klobučar M, Grbčić P, Pavelić SK, Jonjić N, Visentin S, Sedić M. Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling. Biochemical and Biophysical Research Communications [Internet]. 2018 September [cited 2024 May 07];503(2):843-848. doi: 10.1016/j.bbrc.2018.06.085

M. Klobučar, P. Grbčić, S. K. Pavelić, N. Jonjić, S. Visentin and M. Sedić, "Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling", Biochemical and Biophysical Research Communications, vol. 503, no. 2, pp. 843-848, September 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:385873. [Accessed: 07 May 2024]

Metadata
Title (english)Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK−mediated signalling
AuthorMarko Klobučar
AuthorPetra Grbčić
AuthorSandra Kraljević Pavelić
AuthorNives Jonjić
AuthorSarah Visentin
AuthorMirela Sedić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of General Pathology and Pathological Anatomy)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Scientific / art field,
discipline and subdiscipline		BIOTECHNICAL SCIENCES
Biotechnology
Molecular Biotechnology
Abstract (english)
Acid ceramidase (ASAH1) has been implicated in the progression and chemoresistance in different cancers. Its role in colon cancer biology and response to standard chemotherapy has been poorly addressed so far. Here, we have investigated ASAH1 expression at the protein level in human colon cancer cell lines and tissues from colon cancer patients, and have examined in vitro the possible link between ASAH1 expression and functional activity of p53 protein whose inactivation is associated with the progression from adenoma to malignant tumour in colon cancer. Finally, we have explored the role of ASAH1 in response and resistance mechanisms to oxaliplatin (OXA) in HCT 116 colon cancer cells. We have demonstrated that human colon cancer cells and colorectal adenocarcinoma tissues constitutively express ASAH1, and that its expression is higher in tumour tissues than in normal colonic mucosa. Furthermore, we found an inverse correlation between ASAH1 expression and p53 functional activity. Obtained data revealed that ASAH1 was involved in HCT 116 cell response to OXA and that anti-proliferative, pro-apoptotic, anti-migratory and anti-clonogenic effects of OXA could be significantly increased by combination treatment with ASAH1 inhibitor carmofur. Increased OXA sensitivity was associated with downregulation of signalling involved in acquired resistance to OXA in colon cancer, in particular transglutaminase 2 and β1 integrin/FAK, which resulted in the suppression of NF-κB and Akt. Thus, combination of OXA with ASAH1 inhibitors could be a promising strategy to counter chemoresistance and improve treatment outcome in advanced colon cancer.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionAccepted version
Journal titleBiochemical and Biophysical Research Communications
Numberingvol. 503, no. 2, pp. 843-848
p-ISSN0006-291X
DOIhttps://doi.org/10.1016/j.bbrc.2018.06.085
URN:NBNurn:nbn:hr:184:385873
Publication2018-09
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S0006291X18313974
Type of resourceText
Access conditionsInstitutional access
Terms of useLicence In copyright icon
Created on2022-02-03 16:09:35